YOLFTbeta
Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd

RCE · AU · Healthcare / Biotechnology

0.37AUD+0.01 (+1.37%)

Price History

Full chart

Market Stats

Previous Close0.365
Open0.37
Day Range0.35 – 0.37
52-Week Range0.30 – 0.73
Volume61.71K
Market Cap99.38M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.05
Dividend Yield0.00%
Beta0.39
50-Day Avg0.3593
200-Day Avg0.4788

About

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase III clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. James Hamilton-Bray Graham GAICD
  • Employees0
  • HeadquartersGovernor Macquarie Tower, Sydney, NSW, Australia, 2000, Australia
  • Websitehttps://www.recce.com.au

Leadership

  • Dr. John K. A. Prendergast Ph.D.Executive Chairman of the Board · b. 1954
  • Mr. James Hamilton-Bray Graham GAICDCEO, MD & Executive Director
  • Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci)Chief Scientific Officer & Executive Director
  • Dr. Justin WardHead of Chemistry, Principal Quality Chemist & Executive Director
  • Mr. Arthur KollarasPrincipal Engineer & Head of Manufacturing
  • Dr. Alan W. Dunton B.Sc., M.D.Chief Medical Advisor & Non Executive Director · b. 1954
  • Mr. Justin ReynoldsChief Financial Officer
  • Mr. Daniel Astudillo B.A., B.Com., M.B.A.Head of Marketing
  • Ms. Maggie NiewidokCompany Secretary

Financials

Income Statement

Currency: AUD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue-38797.14K113.85K177.02K139.29K1.29M679.62K1.12M1.64M3.08M4.37M5.03M7.51M-
Growth (%)--+25001.29%+17.20%+55.48%-21.31%+825.03%-47.26%+65.05%+45.97%+88.41%+41.50%+15.19%+49.33%-
Cost of Revenue13.00K33.55K61.01K111.12K16.66K25.51K53.12K56.09K200.82K295.63K187.67K217.16K7.22M10.45M356.40K
Gross Profit--33.17K36.13K2.73K160.36K113.78K1.24M623.54K920.91K1.34M2.90M4.15M-2.19M-2.94M-356.40K
Gross Margin--8570.03%37.19%2.40%90.59%81.68%95.88%91.75%82.10%81.94%93.92%95.03%-43.52%-39.12%-
Operating Expense-259.16K308.32K452.64K4.98M3.30M4.16M4.04M6.33M16.71M17.05M21.47M19.86M19.94M22.81M
Operating Income--292.33K-272.19K-449.92K-4.82M-3.18M-2.92M-3.42M-5.41M-15.36M-14.15M-17.33M-22.05M-22.88M-23.16M
Operating Margin--75536.43%-280.20%-395.17%-2723.60%-2286.23%-226.66%-503.09%-482.10%-938.36%-458.69%-396.90%-438.54%-304.71%-
EBITDA--286.55K-263.83K-439.62K-4.95M-3.16M-2.86M-2.68M-5.13M-14.77M-13.87M-16.99M-21.35M-20.33M-22.81M
EBITDA Margin--74044.19%-271.59%-386.13%-2794.93%-2267.91%-221.60%-393.81%-457.44%-902.15%-449.65%-389.17%-424.67%-270.81%-
Net Income--292.46K-272.42K-450.17K-4.84M-3.03M-1.67M-2.79M-4.32M-13.51M-10.99M-13.08M-17.66M-21.43M-14.96M
Net Income Margin--75571.06%-280.43%-395.39%-2734.36%-2172.01%-129.94%-410.40%-384.83%-825.30%-356.12%-299.58%-351.24%-285.37%-
R&D-8.82K8.66K53.88K142.25K999.36K372.17K416.35K1.99M5.56M6.22M7.17M7.04M10.24M-
R&D as % of Total Revenue-2279.33%8.91%47.32%80.36%717.44%28.88%61.26%176.98%339.36%201.74%164.19%140.05%136.41%-
Interest Expense013422809.04K2.41K54.31K56.69K56.44K12.14K11.93K183.26K846.85K1.26M1.66M
Interest Expense % of Total Revenue-34.63%0.23%0.00%5.11%1.73%4.21%8.34%5.03%0.74%0.39%4.20%16.84%16.78%-

Balance Sheet

Currency: AUD2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets32.00K79.63K148.07K4.99M3.72M1.46M1.14M922.18K3.24M21.68M12.62M2.56M6.37M12.41M8.53M
Total Liabilities-154.57K203.81K272.47K206.80K874.44K448.82K1.33M931.53K1.18M2.56M5.14M15.89M15.47M25.25M
Total Equity32.00K-75.20K-56.19K4.71M3.51M590.14K694.91K-405.60K2.31M20.50M10.06M-2.59M-9.52M-3.05M-16.72M
Cash1.00K42.90K94.10K4.89M3.59M1.09M679.72K403.38K2.68M20.87M11.58M1.56M4.42M10.45M2.69M
Total Debt----6.98K322.58K2.86K737.41K83.23K126.95K74.76K250.57K811.19K10.77M10.44M
Net Debt--42.90K-94.10K-4.89M-3.58M-929.15K-676.86K334.02K-2.60M-20.75M-11.51M-1.31M-3.60M319.44K7.75M

Cash Flow

Currency: AUD2013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-11.43K-296.14K-1.61M-2.50M-1.73M-2.61M-3.81M-7.86M-9.01M-12.69M-13.01M-20.44M-9.89M
Investing Cash Flow--35.25K-35.25K-18.36K-246.08K-177.76K-89.93K-5.94K-76.01K-40.34K-38.63K-141.90K-443.90K123.60K
Financing Cash Flow-689.00K689.00K4.77M243.00K1.50M2.43M6.09M26.12M-240.50K2.71M16.00M26.92M2.01M
Capital Expenditure035.25K35.25K78.06K246.08K177.76K89.93K5.94K76.01K40.34K38.63K141.90K26.35K61.96K
Free Cash Flow-11.43K-331.39K-1.69M-2.74M-1.91M-2.70M-3.81M-7.93M-9.05M-12.73M-13.15M-20.47M-9.95M
Dividends Paid---00--1.72M1.72M1.72M----
FCF to OCF-100.00%111.90%104.86%109.85%110.26%103.44%100.16%100.97%100.45%100.30%101.09%100.13%100.63%
Dividend Paid to FCF---0.00%0.00%---45.07%-21.67%-18.99%----

Earnings

Report DateAug 25, 2016Feb 3, 2017Sep 1, 2017Feb 28, 2018Aug 31, 2018Feb 27, 2019Aug 30, 2019Feb 27, 2020Aug 28, 2020Feb 25, 2021Aug 31, 2021Feb 28, 2022Aug 31, 2022Feb 27, 2023Feb 27, 2025Aug 29, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.00-0.00--0.000.00
EPS Actual-0.09-0.02-0.02-0.01-0.01-0.01-0.02-0.01-0.02-0.08-0.02-0.04-0.15-0.05-0.03-0.06
Surprise----------------
Timing-----------Pre-marketAfter-hoursAfter-hours--

Key Statistics & Ratios

Market Cap99.38M
Enterprise Value108.65M
Trailing P/E0.00
Forward P/E0.00
Price / Sales10.50
Price / Book183.30
EPS-0.05
Book Value-0.064
Revenue (TTM)9.47M
Gross Profit (TTM)1.24M
EBITDA-13.79M
Profit Margin-158.06%
Operating Margin20.43%
Return on Equity-1277.63%
Return on Assets-82.75%
Shares Outstanding305.77M
Shares Float219.81M
Beta0.39
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%